The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty

McMahon, Stephen B.; Dargan, Paul I.; Lanas, Fernando; Wiffen, Philip J

doi:10.1080/03007995.2020.1847718

Cited by 31 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The "Pain in Europe" study demonstrates the effect of pain syndrome on the life quality and psychoemotional condition: 13 % of the surveyed patients had to retire due to pain, 19 % lost their jobs, 21 % were diagnosed with depression, over 40 % reported a feeling of helplessness and a failure to interpret the reality or to function properly [12]. The NSAIDs are the most effective medications in terms of spine and joint pain treatment [6]. Our analysis of the EuroQol-5D scale findings, the Group I reported a significant improvement of the following parameters: walking, self-care, everyday activity, pain intensity and depression, by 45 % (t = 4.19, р = 0.002).…”

Section: Discussionmentioning

confidence: 99%

“…In the acute and chronic pain studies, the topical NSAIDs are well tolerated and bring a minimum risk of systemic adverse effects. The highest efficacy of topical NSAIDs is observed in cases of pain occurring due to sports injuries and straining [6]. The ketoprofen gel is able to reach the highest local concentration in the tissues rather than in blood plasma [13].…”

Section: Discussionmentioning

confidence: 99%

“…The LBP is widely-spread across the world: in high-, moderate-, and low-income countries [2]. It causes a lot of significant healthcare and disabilityrelated spendings [3], and exceeds costs of cardiovascular, cancer and diabetes care [6]. If the acute low back pain turns chronic, it may become a serious medical and socio-economic issue [5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Эффективность И Безопасность Лечения Препаратом Фастум® Гель У Лиц С Болью В Нижней Части Спины

Povoroznyuk¹,

Musiienko²,

Zaverukha³

et al. 2021

PJS

View full text Add to dashboard Cite

Background. The purpose was to study the effectiveness and safety of Ketoprofen gel (Fastum gel) therapy in patients with low back pain (LBP) caused by degenerative-dystrophic changes of the spine. Materials and methods. 24 males and females aged 50-69 years with LBP lasting over 14 days were examined, with a further division into two groups. Group I – 12 patients received thin ketoprofen applications on the lumbar region 2 times a day for 10 days. Group II – 12 patients who received thin applications of Vaseline on the same area 2 times a day for 10 days. Patients used the study drugs as a monotherapy. Examination was performed before the treatment initiation, after 10 and 20 days of treatment. Results. Patients receiving ketoprofen applications had a significantly reduced pain intensity registered by all four components of VAS and the Roland-Morris questionnaire. At the same time, the functional capacity by Schober (t = 3.54, p = 0.005) and Tomayer (t = 3.08, p = 0.01) tests was significantly improved. The quality of life according to the EuroQul-5D scale in patients who used the topical ketoprofen significantly increased by 45 % (t = 4.19, p = 0.002), and life expectancy according to the Oswestry questionnaire by 39.3 % after 10 days of treatment (t = 3.9, p = 0.002). 75 % of patients from the main group and 33.3 % from the comparison group assessed the effectiveness of treatment as high according to the Likert index. Neither group reported localized nor systemic side effects. Conclusions. Monotherapy of ketoprofen gel significantly reduced the intensity of pain and improved the functional capacity of patients with LBP. The absence of side effects during treatment indicates its high safety profile for patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Эффективность И Безопасность Лечения Препаратом Фастум® Гель У Лиц С Болью В Нижней Части Спины

Povoroznyuk¹,

Musiienko²,

Zaverukha³

et al. 2021

PJS

View full text Add to dashboard Cite

show abstract

“…Musculoskeletal disease is the leading global cause of disability 2 . Worldwide, 20-33% of people live with painful and debilitating musculoskeletal diseases that affect a diverse range of functionally distinct tissues including tendon, cartilage, ligament, capsule, synovium, muscle and bone 3,4 . Given the ubiquity of musculoskeletal tissue, which comprises at least one-third of the weight of a human body, it is perhaps unsurprising that disease and traumatic injury affects the musculoskeletal system at all life stages, from development through to maturation and ageing 5 Mapping the musculoskeletal system therefore presents an exciting challenge for the research community owing to the diversity of tissues and joints involved and the high burden of musculoskeletal disease.…”

Section: The Musculoskeletal Hca Networkmentioning

confidence: 99%

Mapping the musculoskeletal system one cell at a time

et al. 2021

View full text Add to dashboard Cite

“…Musculoskeletal pain is the most common complaint in the general population and the leading cause of years lost to disability [ 1 , 2 ]. An estimated prevalence of 20% to 40% was reported globally with foreseen increasing individual and societal burden in the next decades [ 3 , 4 ]. A clinically relevant entity of multisite musculoskeletal pain (MSMP) has been defined, as musculoskeletal pain rarely occurs at single site [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Lipidomic Profiling Identifies Serum Lipids Associated with Persistent Multisite Musculoskeletal Pain

Liu

Tian

et al. 2022

Metabolites

View full text Add to dashboard Cite

Objective: Lipid mediators have been suggested to have a role in pain sensitivity and response; however, longitudinal data on lipid metabolites and persistent multisite musculoskeletal pain (MSMP) are lacking. This study was to identify lipid metabolic markers for persistent MSMP. Methods: Lipidomic profiling of 807 lipid species was performed on serum samples of 536 participants from a cohort study. MSMP was measured by a questionnaire and defined as painful sites ≥4. Persistent MSMP was defined as having MSMP at every visit. Logistic regression was used with adjustment for potential confounders. The Benjamini–Hochberg method was used to control for multiple testing. Results: A total of 530 samples with 807 lipid metabolites passed quality control. Mean age at baseline was 61.54 ± 6.57 years and 50% were females. In total, 112 (21%) of the participants had persistent MSMP. Persistent MSMP was significantly associated with lower levels of monohexosylceramide (HexCer)(d18:1/22:0 and d18:1/24:0), acylcarnitine (AC)(26:0) and lysophosphatidylcholine (LPC)(18:1 [sn1], 18:2 [sn1], 18:2 [sn2], and 15-MHDA[sn1] [104_sn1]) after controlling for multiple testing. After adjustment for age, sex, body mass index, comorbidities, and physical activity, HexCer(d18:1/22:0 and d18:1/24:0) and LPC(15-MHDA [sn1] [104_sn1]) were significantly associated with persistent MSMP [Odds Ratio (OR) ranging from 0.25–0.36]. Two lipid classes—HexCer and LPC—were negatively associated with persistent MSMP after adjustment for covariates (OR = 0.22 and 0.27, respectively). Conclusions: This study identified three novel lipid signatures of persistent MSMP, suggesting that lipid metabolism is involved in the pathogenesis of persistent pain.

show abstract

The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty

Abstract: The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty, Current Medical Research and Opinion,

Cited by 31 publications

References 20 publications

Эффективность И Безопасность Лечения Препаратом Фастум® Гель У Лиц С Болью В Нижней Части Спины

Эффективность И Безопасность Лечения Препаратом Фастум® Гель У Лиц С Болью В Нижней Части Спины

Mapping the musculoskeletal system one cell at a time

Lipidomic Profiling Identifies Serum Lipids Associated with Persistent Multisite Musculoskeletal Pain

Contact Info

Product

Resources

About